JHL has research facilities in both Hsinchu and Wuhan, in Hubei province, and is aiming to raise US$250 million through a re-listing in Hong Kong. Photo: Rafe Swan/cultura/Corbis

Taiwan cancer drugs developer seeks Hong Kong bond issue ahead of IPO after delisting from Taipei

JHL Biotech raises US$106m from a convertible bond issue, ahead of its planned Hong Kong IPO aiming to raise some US$250m

Topic |   Pharmaceuticals

TOP PICKS

JHL has research facilities in both Hsinchu and Wuhan, in Hubei province, and is aiming to raise US$250 million through a re-listing in Hong Kong. Photo: Rafe Swan/cultura/Corbis
READ FULL ARTICLE